Asuragen will now provide comprehensive targeted DNA mutation analysis of tumor samples to identify both known and de novo mutations within FFPE and FNA specimens.

Services will also include both Asuragen’s SuraSeq custom cancer panels and the Ion AmpliSeq cancer panel.

Life Technologies Marketing and Business Development vice president Maneesh Jain said Asuragen has been an early adopter of the PGM platform, and they are pleased to have this company as one of their certified service providers.

Asuragen Pharmacogenomic Services Division senior vice president and GM Carol Berry said the PGM next generation sequencing allows them to expand their proven platform of molecular sample interrogation to assist their customers in their targeted drug and diagnostic development programs.